Agios Pharmaceuticals (AGIO) Expected to Announce Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is expected to be announcing its earnings results before the market opens on Thursday, February 20th. Analysts expect the company to announce earnings of ($1.69) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Agios Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ:AGIO opened at $32.81 on Thursday. Agios Pharmaceuticals has a 12-month low of $24.69 and a 12-month high of $62.58. The company has a market cap of $1.87 billion, a PE ratio of 2.89 and a beta of 0.88. The stock has a 50 day moving average of $36.28 and a 200 day moving average of $43.58.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.93% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AGIO has been the topic of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Scotiabank upped their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, StockNews.com raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $56.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.